Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, randomized, placebo controlled, two part, two session balanced, crossover study to evaluate visual changes in healthy male subjects aged 18 - 55 years after receiving: 1. at least 15 doses of 20 mg vardenafil, compared to placebo and 2. two doses of sildenafil, 200 mg compared to placebo.

Next Previous
X
Search
Trial Profile

A double blind, randomized, placebo controlled, two part, two session balanced, crossover study to evaluate visual changes in healthy male subjects aged 18 - 55 years after receiving: 1. at least 15 doses of 20 mg vardenafil, compared to placebo and 2. two doses of sildenafil, 200 mg compared to placebo.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vardenafil (Primary) ; Sildenafil
  • Indications Erectile dysfunction
  • Focus Pharmacodynamics
  • Sponsors Bayer

    • Most Recent Events

    • 09 Mar 2009 Actual patient number (63) added as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Bayer HealthCare added as trial affiliate as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top